Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

July 19, 2005 06:00 ET

Swiss Medica Welcomes Experienced Health Industry Professional Charles Orr to Board of Directors

TORONTO, ONTARIO--(CCNMatthews - July 19, 2005) -

After 18 months as chairman of the company's Board of Advisors, Mr. Orr deepens his commitment to Swiss Medica as a director

Swiss Medica, Inc. (OTCBB:SWME) today announced the appointment of Charles Orr to its Board of Directors. Mr. Orr was President and CEO of Shaklee Corporation from 1993 to 2000, where sales grew to $700 million annually. Mr. Orr currently serves on the Board of Directors of Herbalife (NYSE:HLF), a leading global healthcare network marketing company, the Direct Selling Education Foundation, and is an advisor to several private companies.

Prior to his work with Shaklee, Mr. Orr held senior management and board of director positions in a variety of life insurance, financial services and technology enterprises including Federated Investors, Continental Insurance, Southwestern Life Insurance Company, Connecticut General Insurance Corporation, Xerox and RCA.

"We are delighted to have someone of Charlie's caliber, experience and depth to join the Swiss Medica Board of Directors," said Raghu Kilambi, CEO of Swiss Medica. "Not only does he have 40 years of business experience and a keen knowledge of how to grow a business based on providing effective, scientifically-proven health solutions, but he has also taken the time to get to know our business throughout the last 18 months as chairman of our Board of Advisors. We look forward to enjoying his continued and valued contribution to Swiss Medica in his new role."

Mr. Orr said he has learned a great deal from working with Swiss Medica. "Swiss Medica is developing clinically proven, patented technologies that address chronic ailments - and provide, safe alternatives to prescription products," he said. "This is a very innovative company. I look forward to being able to make a greater contribution to Swiss Medica as it builds a loyal consumer base and sustained success."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com

Swiss Medica's flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Fusion Communications
    Public Relations Contact:
    Dean Mailey
    (604) 218-6767
    dean@fusioncom.ca
    or
    Stern & Co.
    Financial Media Contact:
    Stan Froelich
    VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com